At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral ...

Instead of focusing on weight loss, focus on developing a healthy body composition—it offers way more health benefits. Here ...

The company said the study involved participants with less fat than those typically enrolled in later-stage obesity studies and that it had expected the drug to have greater effec ...

Wave Life Sciences stock crashed Thursday after the company's much-hyped "body composition" drug led to just 1% weight loss in six months.

WAVE Life Sciences (NASDAQ:WVE) highlighted positive interim data from the ongoing Phase 1 INLIGHT trial of WVE-007, a GalNAc ...

Understanding your body goes well beyond a mere number on the scale. That's where DEXA (Dual-Energy X-ray Absorptiometry) ...

Every time Julia publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

As the body ages, subtle hormonal shifts begin to reshape where fat is stored, with important consequences for long-term ...

A recent study found that excess body fat in the abdomen and pelvis may predict poor treatment response in patients with multiple myeloma. While studies have demonstrated that excess body weight is a ...

Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive ...

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted ...